Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas

Relevance. Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative malignancies that account for approximately 10% of adult non-Hodgkins lymphomas. Despite the variety of PTCL subtypes, CHOP-like regimens are the standard first-line therapy in most cases....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina V. Poddubnaya, Elena A. Bariakh, Sergei V. Voloshin, Liliia G. Gorenkova, Kamil D. Kaplanov, Alla M. Kovrigina, Nataliia B. Mikhailova, Tatiana I. Pospelova, Vadim V. Ptushkin, Gaiane S. Tumian, Natalia A. Falaleeva, Gulnara N. Khusainova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	cd30-positive peripheral t-cell lymphomas brentuximab vedotin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fe0771127994485f9b77da21b6852fed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe0771127994485f9b77da21b6852fed
record_format	dspace
spelling	oai:doaj.org-article:fe0771127994485f9b77da21b6852fed2021-11-30T16:55:01ZModern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas1815-14341815-144210.26442/18151434.2021.1.200698https://doaj.org/article/fe0771127994485f9b77da21b6852fed2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70485/51401https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Relevance. Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative malignancies that account for approximately 10% of adult non-Hodgkins lymphomas. Despite the variety of PTCL subtypes, CHOP-like regimens are the standard first-line therapy in most cases. At the same time, the level of complete remissions at the using these schemes is about 39%, the 2-year event-free survival rate does not exceed 45%. The possibilities of subsequent therapy of patients are very limited: the median overall survival after relapse is only 6.5 months. The most significant results were obtained only in patients with relapses of anaplastic large cell lymphoma after the use of the targeted drug brentuximab vedotin BV (conjugate of a CD30-directed monoclonal antibody and an antitumor agent). Given the favorable safety profile of this drug, a phase 3, double-blind, randomized study (ECHELON-2) was initiated and conducted comparing the efficacy and safety of the combination of BV with CHP (cyclophosphamide, doxorubicin, prednisolone) (BV+CHP) and standard CHOP regimen in previously untreated patients with CD30-positive PTCL. Aim. Discuss the entire spectrum of unmet medical needs in the treatment of patients with PTCL and adapt existing approaches taking into account new therapeutic options (results of the protocol ECHELON-2). Results. The advantages of the BV+CHP regimen in the treatment of previously untreated patients with CD30-positive PTCL were recognized as convincing. Given the lack of real therapeutic options, it is recommended to register in Russia a broad indication for BV: treatment of previously untreated CD30-expressing peripheral T-cell lymphomas (in combination with CHP). It was considered expedient to include the BV+CHP regimen in the updated Clinical Guidelines for the Treatment of Lymphoproliferative Diseases.Irina V. PoddubnayaElena A. BariakhSergei V. VoloshinLiliia G. GorenkovaKamil D. KaplanovAlla M. KovriginaNataliia B. MikhailovaTatiana I. PospelovaVadim V. PtushkinGaiane S. TumianNatalia A. FalaleevaGulnara N. KhusainovaIP Habib O.N.articlecd30-positive peripheral t-cell lymphomasbrentuximab vedotinNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 167-171 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	cd30-positive peripheral t-cell lymphomas brentuximab vedotin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cd30-positive peripheral t-cell lymphomas brentuximab vedotin Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Irina V. Poddubnaya Elena A. Bariakh Sergei V. Voloshin Liliia G. Gorenkova Kamil D. Kaplanov Alla M. Kovrigina Nataliia B. Mikhailova Tatiana I. Pospelova Vadim V. Ptushkin Gaiane S. Tumian Natalia A. Falaleeva Gulnara N. Khusainova Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
description	Relevance. Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative malignancies that account for approximately 10% of adult non-Hodgkins lymphomas. Despite the variety of PTCL subtypes, CHOP-like regimens are the standard first-line therapy in most cases. At the same time, the level of complete remissions at the using these schemes is about 39%, the 2-year event-free survival rate does not exceed 45%. The possibilities of subsequent therapy of patients are very limited: the median overall survival after relapse is only 6.5 months. The most significant results were obtained only in patients with relapses of anaplastic large cell lymphoma after the use of the targeted drug brentuximab vedotin BV (conjugate of a CD30-directed monoclonal antibody and an antitumor agent). Given the favorable safety profile of this drug, a phase 3, double-blind, randomized study (ECHELON-2) was initiated and conducted comparing the efficacy and safety of the combination of BV with CHP (cyclophosphamide, doxorubicin, prednisolone) (BV+CHP) and standard CHOP regimen in previously untreated patients with CD30-positive PTCL. Aim. Discuss the entire spectrum of unmet medical needs in the treatment of patients with PTCL and adapt existing approaches taking into account new therapeutic options (results of the protocol ECHELON-2). Results. The advantages of the BV+CHP regimen in the treatment of previously untreated patients with CD30-positive PTCL were recognized as convincing. Given the lack of real therapeutic options, it is recommended to register in Russia a broad indication for BV: treatment of previously untreated CD30-expressing peripheral T-cell lymphomas (in combination with CHP). It was considered expedient to include the BV+CHP regimen in the updated Clinical Guidelines for the Treatment of Lymphoproliferative Diseases.
format	article
author	Irina V. Poddubnaya Elena A. Bariakh Sergei V. Voloshin Liliia G. Gorenkova Kamil D. Kaplanov Alla M. Kovrigina Nataliia B. Mikhailova Tatiana I. Pospelova Vadim V. Ptushkin Gaiane S. Tumian Natalia A. Falaleeva Gulnara N. Khusainova
author_facet	Irina V. Poddubnaya Elena A. Bariakh Sergei V. Voloshin Liliia G. Gorenkova Kamil D. Kaplanov Alla M. Kovrigina Nataliia B. Mikhailova Tatiana I. Pospelova Vadim V. Ptushkin Gaiane S. Tumian Natalia A. Falaleeva Gulnara N. Khusainova
author_sort	Irina V. Poddubnaya
title	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
title_short	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
title_full	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
title_fullStr	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
title_full_unstemmed	Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas
title_sort	modern approaches in the first line treatment of cd30-positive peripheral t-cell lymphomas
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/fe0771127994485f9b77da21b6852fed
work_keys_str_mv	AT irinavpoddubnaya modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT elenaabariakh modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT sergeivvoloshin modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT liliiaggorenkova modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT kamildkaplanov modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT allamkovrigina modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT nataliiabmikhailova modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT tatianaipospelova modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT vadimvptushkin modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT gaianestumian modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT nataliaafalaleeva modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas AT gulnarankhusainova modernapproachesinthefirstlinetreatmentofcd30positiveperipheraltcelllymphomas
_version_	1718406481671356416

Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas

Ejemplares similares